The present study evaluated the sensitivity and specificity of important proteomic salivary biomarkers; IL-6, IL-8, and sCD44 in the early detection of oral cancer, and any possible associations with risk factors of oral cancer in an Egyptian population. The present investigation was conducted on 100 individuals; 25 healthy controls, 25 patients having oral potentially malignant disorders (OPMDs) with dysplasia; 25 patients having OPMDs without dysplasia, and 25 oral cancer patients. Demographic data modified gingival index, oral hygiene level, and salivary levels of the biomarkers were assessed. Salivary levels of IL-6, IL-8, and sCD44 progressively increased with increased disease severity. Salivary IL-8 and IL-6 levels possess a discriminating potential from normal tissue through different degrees of dysplasia to oral cancer, sCD44 levels had a discriminating power between normal and dysplastic tissues with high sensitivity and specificity. A positive correlation was found between the three biomarkers and the grade of oral squamous cell carcinoma (OSCC) and with different risk factors. This is the first study that evaluated multiple salivary proteomic biomarkers in the Egyptian population, and the results validate the ability of IL-6, IL-8, and sCD44 to be used as sensitive diagnostic and prognostic biomarkers for screening and early detection of oral cancer.
26 December 2024 in European Journal of Oral Sciences
Aim: Burning mouth syndrome (BMS) is a debilitating chronic burning sensation in the oral cavity with no identifiable cause. The present research was conducted to evaluate the prevalence profile
1 January 2025 in International Journal of Dentistry
Aims: The present study aspired to evaluate the impact of the adjunctive use of omega‐3 with nonsurgical periodontal therapy on clinical parameters as well as local and systemic chemerin levels as a marker of cardiovascular disease risk in periodontitis patients with diabetes. Methods: This randomized clinical trial was performed on thirty periodontitis patients with type II diabetes divided into two equal groups, both treated by nonsurgical periodontal treatment with the adjunctive use of daily 1000 mg Omega‐3FAs in group I only for 6 months. Patients were reexamined after 2 weeks (baseline), 3, and 6 months for recording the clinical parameters as follows: plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment loss (CAL). Chemerin levels were assessed in both serum and GCF samples, HbA1c levels were also assessed. Results: Omega‐3FAs‐treated group recorded a more statistically significant improvement in clinical parameters compared to the control group, particularly concerning PD and CAL. A statistically significant reduction of HbA1c levels between baseline, 3 and 6 m values was encountered in Omega‐3FAs treated group, while no significant difference was evident in the control group. Additionally, Omega‐3FAs treated group recorded a more statistically significant reduction of GCF and serum chemerin levels in comparison to the control group after 6 months of therapy. Conclusion: The adjunctive use of omega‐3FAs with nonsurgical periodontal therapy has resulted in significant improvement of clinical periodontal parameters and glycemic control in periodontitis patients with type II diabetes, alongside the additional benefit of reducing both local and systemic chemerin levels, a biomarker for cardiovascular risk. Trial Registration: Clinical Trial Registry identifier: NCT06463535